2. Metabolic Enzyme/Protease
  3. Thrombin
  4. Sulodexide

Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease.

For research use only. We do not sell to patients.

Sulodexide Chemical Structure

Sulodexide Chemical Structure

CAS No. : 57821-29-1

Size Price Stock Quantity
Solvent
250 LSU USD 50 In-stock
1 mL   Get quote  
5 mL   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Sulodexide Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease[1].

In Vitro

Sulodexide (0–200 μg/mL, 24 hours) promotes fibronectin and collagen type III synthesis in mouse mesangial cells[2].
Sulodexide (50 µg/mL, 48 hours) significantly inhibits capillarization marker expression in LSECs[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sulodexide Related Antibodies

Western Blot Analysis[2]

Cell Line: Mouse mesangial cells (diabetic nephropathy)
Concentration: 0–200 μg/mL
Incubation Time: 24 hours
Result: Increased synthesis of fibronectin and collagen type III in cells, further enhanced under high glucose conditions.

Real Time qPCR[4]

Cell Line: Mouse liver sinusoidal endothelial cells (LSECs; liver fibrosis)
Concentration: 50 µg/mL
Incubation Time: 48 hours
Result: Significantly reduced expression of capillarization markers Edn1 and CD34.
In Vivo

Sulodexide (1 mg/kg, p.o., once daily for 12 weeks) significantly improves proteinuria and renal function in Streptozotocin (HY-13753)-induced type I diabetic nephropathy in mice[2].
Sulodexide (5 mg/kg and 15 mg/kg, i.p., once daily for 5 days) significantly inhibits retinal neovascularization and suppressed pro-angiogenic protein expression in the oxygen-induced retinopathy model in ICR mice[3].
Sulodexide (20 mg/kg, i.g., once daily for 4 weeks) significantly attenuats fibrosis in the Thioacetamide (HY-Y0698)-induced liver fibrosis model in mice[4].
Sulodexide (40 mg/kg, i.g., single dose) significantly improvs survival and reduced lung injury in the LPS (HY-D1056)-induced endotoxemia model in C57BL/6J mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Streptozotocin (HY-13753)-induced type I diabetic nephropathy in C57BL/6 mice model[2]
Dosage: 1 mg/kg
Administration: Oral gavage (p.o.), once daily for 12 weeks
Result: Significantly reduced urinary albumin levels, improved renal function, increased GBM perlecan expression, reduced collagen I and IV deposition, and ERK activation.
Animal Model: Oxygen-induced retinopathy (OIR) model in ICR mice[3]
Dosage: 5 mg/kg and 15 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 5 days
Result: Significantly reduced avascular area, decreased neovascular tufts and lumens.
Significantly inhibited expression of MMP-2, MMP-9, and VEGF
Animal Model: Thioacetamide (HY-Y0698)-induced liver fibrosis in C57BL/6 mice model[4]
Dosage: 20 mg/kg
Administration: Intragastric administration (i.g.), once daily for 4 weeks
Result: Significantly reduced expression of fibrosis markers (Col1a1 and α-SMA), decreased hydroxyproline levels, and inhibited ECM deposition in liver tissue.
Animal Model: LPS (HY-D1056)-induced endotoxemia in C57BL/6J mice model[5]
Dosage: 40 mg/kg
Administration: Intragastric administration (i.g.), single dose
Result: Significantly reduced plasma Syndecan-1 (SDC1) levels, increased survival rate, reduced lung injury, and restored endothelial glycocalyx damage.
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Sulodexide]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sulodexide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sulodexide57821-29-1Thrombinantithromboticprofibrinolyticischemiareperfusion injuryacute peritonitisintermittent claudicationperipheral arterial occlusive diseasepost-myocardial infarction,Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sulodexide
Cat. No.:
HY-100897
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.